Sagimet Biosciences Inc. (SGMT)
Nasdaq: SGMT · Pharmaceutical Preparations · San Mateo, CA · filing with the SEC since 2007
Who owns Sagimet Biosciences Inc.
As filed with the SECHolders of 5% or more
3
Blackrock, Inc. holds 7.8% of Class A Stock, as its SCHEDULE 13G filed Jul 30, 2026 says.
Directors and officers
11
report now, of 18 people on the record since 2023. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G · filed Jul 30, 2026 · Class A Stock
Commodore Capital LP
SCHEDULE 13G · filed Oct 7, 2026 · Series A Common Stock, $0.0001 par value per share
Balyasny Asset Management L.P.
SCHEDULE 13G · filed Aug 14, 2026 · Common Stock Series A
AP11 Limited
SCHEDULE 13G/A · filed Jun 24, 2025 · Series A common stock · reported falling below 5%, from 5.4% in May 20, 2025
Woodline Partners LP
SCHEDULE 13G/A · filed Nov 14, 2025 · Series A Common Stock, par value $0.0001 per share · reported falling below 5%, from 8.3% in Aug 14, 2025
Blue Owl Capital Holdings LP
SCHEDULE 13G/A · filed Feb 14, 2025 · Series A common stock, $0.0001 par value per share · reported falling below 5%
KPCB Pandemic and Bio Defense Fund, LLC
SCHEDULE 13G/A · filed Dec 18, 2025 · Series A Common Stock, $0.0001 par value per share · reported falling below 5%
Point72 Asset Management, L.P.
SCHEDULE 13G/A · filed Aug 14, 2025 · Series A Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.7% in May 15, 2025
New Enterprise Associates 13, L.P.
SCHEDULE 13G/A · filed May 13, 2025 · Series A Common Stock, $0.0001 par value per share · reported falling below 5%
What SGMT reports owning in othersstakes of 5% or more, and other ties
Sagimet Biosciences Inc. reports no stake in another company in the record.
Insider tradesForm 4
10sales
0purchases
4sales on a scheduled plan
5people selling
$4.9Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window5 of 26 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Kemble George | Executive Chairman | 4 | $4.2M | 4 | 0 | $0 |
| Happel David | President & CEO | 2 | $600,000 | 0 | 0 | $0 |
| Rozek Elizabeth | Chief Legal & Admin. Officer | 2 | $100,000 | 0 | 0 | $0 |
| Chauche Thierry | Chief Financial Officer | 1 | $0 | 0 | 0 | $0 |
| Martins Eduardo Bruno | Chief Medical Officer | 1 | $0 | 0 | 0 | $0 |